A Phase 2 interventional study of Brenipatide and Placebo in Schizophrenia, sponsored by Eli Lilly and Company. Recruiting at 101 sites in 7 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Schizophrenia by Eli Lilly and Company — 2 open to participants now, 2 under way, none of them phase 3. Schizophrenia · Eli Lilly and Company.
Among the 33 studies in Schizophrenia by Eli Lilly and Company, this one is the 9th largest by planned enrollment of the 29 interventional ones that give a count, is the only one that started in 2026, is one of 2 in phase 2, and was the 33rd registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →2 of the 33 studies in Schizophrenia by Eli Lilly and Company are open now, in 7 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 10 · Phase 4 16
First in 2001; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 450 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 203 across the 29 interventional studies, 2,566 across the 2 observational. Of the 31 that completed or were terminated, 9 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
1 of the studies in Schizophrenia by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07410507Eli Lilly and CompanyA Study of Brenipatide in Adult Participants With Schizophrenia | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 33 studies in Schizophrenia by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia.
The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment period will last a maximum of 12 months, and the follow up period will last approximately 2 months. The length of time of your study participation may last up to approximately 15 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Are reliable and willing to make themselves available for the duration of the study and attend required study visits, and are willing and able to follow study procedures as required, such as
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brenipatide administered subcutaneously (SC) + SoC.
Drug: Brenipatide
Placebo administered SC + SoC.
Drug: Placebo
Administered SC
Also known as: LY3537031
Administered SC
Percent Change from Baseline in Body Weight in Participants with a Baseline Body Mass Index ≥25.0 Kilograms per Meter Squared (kg/m²)
Time frame: Baseline, Week 52
Change from Baseline on Neurocognitive Battery Composite Test Score at Week 36
Time frame: Baseline, Week 36
Time to Relapse
Time to relapse defined as days from randomization to the dates on which the participant meets any relapse criteria.
Time frame: Randomization up to Week 52
Change from Baseline in Clinical Global Impression - Severity - Schizophrenia (CGI-S-SCH)
Time frame: Baseline, Week 52
Change from Baseline in Patient Global Impression - Severity
Time frame: Baseline, Week 52
Change from Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score
Time frame: Baseline, Week 52
Change from Baseline on the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) Total Completion Time
Time frame: Baseline, Week 52
Change from Baseline on the Schizophrenia Cognition Rating Scale (SCoRS) Total Score
Time frame: Baseline, Week 52
Percentage of Participants with Body Mass Index ≥25 kg/m2 (BMI) Who Achieve Body Weight Reduction of ≥5%
Time frame: Baseline up to 52 Weeks
Pharmacokinetic (PK): Average Steady State Plasma Concentration (Cavg) of Brenipatide
Time frame: Baseline up to Week 52
Number of Participants with Treatment-Emergent Anti-Drug Antibodies
Time frame: Baseline up to Week 52
Showing the first 100 of 101 sites across 7 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal should be approved by an independent review panel and researchers should sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Started Feb 2026 (actual). Primary completion is estimated for Nov 2027, 21 months after the start.
Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's planned 21 months is close to that.
Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brenipatide